Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2012

View Archived Issues

Astellas Pharma highlights progress of third quarter of fiscal 2011

Maruho acquires U.S. company

Amarin gives update on FDA's review of AMR-101 NDA

Synthetic mast cell microparticles serve as vaccine adjuvants

Superhydrophobic materials allowing slow drug release designed in U.S.

New phase III data support once-weekly exenatide use for diabetes type 2

New prostanoid DP2 receptor antagonists prepared at Ironwood Pharmaceuticals

New metabotropic glutamate mGlu4 receptor modulators identified

Bayer Schering Pharma divulges novel protein kinase inhibitors

Nippon Chemiphar patents new candidate therapies for urinary incontinence

Novartis announces new prostanoid IP1 receptor agonists

Addex Pharmaceuticals designs new modulators of metabotropic glutamate mGlu4 receptor

RedHill Biopharma clear to conduct advanced-stage RHB-102 trial

Tiltan Pharma begins phase II study of TL-118

Soligenix announces promising results on SGX-201

Burnet Institute to receive grant for tuberculosis biomarkers

Compendia Bioscience enters partnership for next-generation cancer therapeutics

PROLOR Biotech reports additional preclinical data on long-acting clotting factor

Biogen Idec to acquire biotechnology company

Ziopharm reports encouraging overall survival data from study in soft tissue sarcoma

Columbia Laboratories transfers progesterone vaginal gel NDA

Phosphagenics reports results from trial of improved oxycodone patch

Phase II letermovir trial meets primary efficacy endpoints

Study provides proof of concept for TransVax cytomegalovirus vaccine

Newron and Meiji Seika Pharma finalize licensing agreement

SuppreMol reports interim phase Ib/IIa SM-101 data

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...